Peter A Forsyth
Overview
Explore the profile of Peter A Forsyth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
3477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ahmed K, Kim Y, Armaghani A, Arrington J, Costa R, Czerniecki B, et al.
Neuro Oncol
. 2025 Jan;
PMID: 39851040
Background: Screening of asymptomatic stage IV breast cancer with brain MRIs is currently not recommended by National Comprehensive Cancer Network (NCCN) Guidelines. The incidence of asymptomatic brain metastasis is not...
2.
Alhaddad H, Ospina O, Khaled M, Ren Y, Vallebuona E, Boozo M, et al.
Cell Rep Med
. 2024 Jun;
5(6):101606.
PMID: 38866016
Leptomeningeal disease (LMD) remains a rapidly lethal complication for late-stage melanoma patients. Here, we characterize the tumor microenvironment of LMD and patient-matched extra-cranial metastases using spatial transcriptomics in a small...
3.
Ahmed K, Kumthekar P, Pina Y, Kim Y, Vogelbaum M, Han H, et al.
JAMA Oncol
. 2024 May;
10(7):984-986.
PMID: 38780965
No abstract available.
4.
Mills M, Uno A, Li P, Liveringhouse C, Kim Y, Oliver D, et al.
Clin Lung Cancer
. 2024 May;
25(5):417-423.e1.
PMID: 38719648
Background: EGFR-targeted therapy (ETT) and immune-checkpoint blockade (ICB) have shown promising results in treating NSCLC brain metastases (BM). However, little is known of their effect in treating leptomeningeal disease (LMD)....
5.
Law V, Smalley I, Evernden B, Baldwin M, Smalley K, Forsyth P
J Vis Exp
. 2024 Apr;
(205).
PMID: 38619274
Melanoma-associated leptomeningeal disease (M-LMD) occurs when circulating tumor cells (CTCs) enter into the cerebral spinal fluid (CSF) and colonize the meninges, the membrane layers that protect the brain and the...
6.
Tang J, Mills M, Nakashima J, Dohm A, Khushalani N, Forsyth P, et al.
J Neurooncol
. 2024 Feb;
166(3):431-440.
PMID: 38310157
Purpose: Upfront dual checkpoint blockade with immune checkpoint inhibitors (ICI) has demonstrated efficacy for treating melanoma brain metastases (MBM) in asymptomatic patients. Whether the combination of stereotactic radiosurgery (SRS) with...
7.
Khaled M, Ren Y, Kundalia R, Alhaddad H, Chen Z, Wallace G, et al.
bioRxiv
. 2024 Jan;
PMID: 38187773
Leptomeningeal disease (LMD) occurs when tumors seed into the leptomeningeal space and cerebrospinal fluid (CSF), leading to severe neurological deterioration and poor survival outcomes. We utilized comprehensive multi-omics analyses of...
8.
Phadke M, Li J, Chen Z, Rodriguez P, Mandula J, Karapetyan L, et al.
J Immunother Cancer
. 2023 Dec;
11(12).
PMID: 38056899
Background: Although the anti-PD-1+LAG-3 and the anti-PD-1+CTLA-4 combinations are effective in advanced melanoma, it remains unclear whether their mechanisms of action overlap. Methods: We used single cell (sc) RNA-seq, flow...
9.
Emmons M, Bennett R, Riva A, Gupta K, Carvalho L, Zhang C, et al.
Nat Commun
. 2023 Nov;
14(1):7759.
PMID: 38030596
Melanomas can adopt multiple transcriptional states. Little is known about the epigenetic drivers of these cell states, limiting our ability to regulate melanoma heterogeneity. Here, we identify stress-induced HDAC8 activity...
10.
Dohm A, Nakashima J, Kalagotla H, Jiang S, Tang J, Bhandari M, et al.
Eur J Cancer
. 2023 Sep;
192:113287.
PMID: 37657227
Background: Immunotherapy and targeted BRAF/MEK inhibitors (i) have revolutionised the systemic management of advanced melanoma. Given the role of stereotactic radiosurgery (SRS) in the local management of brain metastases, we...